See if You Qualify

Fill out the form below to see if you ​may be a good fit for the ​study. Your personal information will only be used for the purposes of the study.

Why participate?

Some benefits of participation include:

  • Get the chance to try an investigational treatment designed to prevent migraine attacks.
  • Receive $575 in compensation upon completing all study tasks
  • Help improve medical research for people with migraine

If you’re taking one of the following medications, you may qualify:

  • Fremanezumab (Ajovy)
  • Erenumab (Aimovig)
  • Eptinezumab (Vyepti)
  • Galcanezumab (Emgality)
  • Rimegepant (Nurtec ODT)
  • Ubrogepant (Ubrelvy)
  • Atogepant (Qulipta)
  • Zavegepant (Zavzpret)

What’s involved?

You’ll be asked to complete questionnaires, download the Click Therapeutics ™ Study App, complete daily activities in the app, and attend two remote visits. All study activities can be done from the comfort of your home.

Frequently asked questions

I’m diagnosed but not currently taking medication, can I still take part?

No, for this particular study, we’re looking specifically for people who are currently taking a CGRP medication for migraine.

Is the treatment safe?

Because the investigational treatment is a smartphone app, it’s considered to be potentially low risk.

How long is the study?

There is an up to 2-week screening period, a 4-week diary entry period, a 12-week study treatment period, and a 1-week follow-up period for a total of about 19-weeks.

Is participation voluntary?

Yes, participation is completely voluntary and can be ended at any time.